Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress of lipoprotein residues in type 2 diabetes mellitus complicated with cardiovascular disease

( views:25, downloads:17 )

Author:: No author available

Journal Title:: Chinese Journal of Diabetes

Issue:: 12

DOI:: 10.3969/j.issn.1006‑6187.2022.12.014

Key Word:: 脂蛋白残粒;糖尿病,2型;心血管疾病

Abstract：脂蛋白残粒(RLP)是升高心血管疾病风险主要原因,T2DM患者RLP升高,RLP产生和清除之间的不平衡可影响T2DM合并心血管疾病的发生发展.炎症作用和泡沫细胞形成促进RLP对T2DM合并心血管疾病的影响.本文综述RLP与T2DM合并心血管疾病关系的研究进展.

Reference

[1]梁纯子,朱满,伍仕敏,等.VAP+技术在高三酰甘油血症患者血浆LDL-C和LDL-P检测中的应用[J].2020,(2).
[2]郭旭,郭凤静,王晓鸥,等.血脂水平对稳定性冠状动脉粥样硬化性心脏病合并糖尿病患者炎症的影响[J].2018,(11).
[3]贺小宁,张雅雯,阮贞,等.中国2型糖尿病患者慢性并发症患病率与次均医疗费用研究[J].2019,(3).
[4]Edward W, Gregg,Desmond E, Williams,Linda, Geiss.Changes in diabetes-related complications in the United States.[J].2014,371(3).
[5]陈瑞瑞,周华.血清载脂蛋白CⅢ、残余脂蛋白胆固醇水平与冠状动脉粥样硬化性心脏病合并2型糖尿病的关系[J].2019,(5).
[6]Eiichi, Araki,Shizuya, Yamashita,Hidenori, Arai,etc.Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.[J].2018,(Spec ).
[7]Santos, Heitor O.,Earnest, Conrad P.,Tinsley, Grant M.,etc.Special Article - Small dense low-density lipoprotein-cholesterol (sdLDL-C): Analysis, effects on cardiovascular endpoints and dietary strategies[J].2020,63(4).
[8]Chinese Society of Cardiology of Chinese Medical Association,Metabolic Cardiovascular Disease Group,中华医学会心血管病学分会代谢性心血管疾病学组,中华心血管病杂志编辑委员会.心血管病合并糖代谢异常患者心血管风险综合管理中国专家共识[J].2021,(7).
[9]Karin A.M. Jandeleit-Dahm,Mark E. Cooper,Muhammad Maqbool.Cardiovascular Disease and Diabetic Kidney Disease[J].2018,38(3).
[10]Joseph,J.J.,Golden,S.H..Type 2 diabetes and cardiovascular disease: What next?[J].2014,21(2).
[11]Varbo,A.,Benn,M.,Tybj?rg-Hansen,A.,etc.Remnant cholesterol as a causal risk factor for ischemic heart disease[J].2013,61(4).
[12]Boden WE,Probstfield JL,Anderson T,etc.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.[J].2011,365(24).
[13]Sagar B, Dugani,Akintunde O, Akinkuolie,Nina, Paynter,etc.Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.[J].2016,(2).
[14]Tani Shigemasa,Yagi Tsukasa,Atsumi Wataru,etc.Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study[J].2017,16(1).
[15]Varbo, Anette,Nordestgaard, Borge G..Remnant lipoproteins[J].2017,28(4).
[16]王迁,李梦涛,曾小峰.持续积累临床证据，提高我国结缔组织病相关肺动脉高压的诊治水平[J].2021,(5).
[17]Priska,Stahel,Changting,Xiao,Avital,Nahmias,etc.Role of the Gut in Diabetic Dyslipidemia.[J].2020,11.
[18]Marja-Riitta Taskinen,Jan Borén.New insights into the pathophysiology of dyslipidemia in type 2 diabetes[J].2015,239(2).
[19]Generoso, Giuliano,Janovsky, Carolina C. P. S.,Bittencourt, Marcio S..Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis[J].2019,26(2).
[20]Si Van Nguyen,Nakamura, Takamitsu,Uematsu, Manabu,etc.Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease[J].2017,69(3).
[21]Baumstark, Daniela,Kremer, Werner,Boettcher, Alfred,etc.H-1 NMR spectroscopy quantifies visibility of lipoproteins, subclasses, and lipids at varied temperatures and pressures[S][J].2019,60(9).
[22]Tada, Hayato,Nohara, Atsushi,Inazu, Akihiro,etc.Remnant lipoproteins and atherosclerotic cardiovascular disease[J].2019,490.
[23]Gan, Wei,Bragg, Fiona,Walters, Robin G.,etc.Genetic Predisposition to Type 2 Diabetes and Risk of Subclinical Atherosclerosis and Cardiovascular Diseases Among 160,000 Chinese Adults[J].2019,68(11).
[24]Wiggin TD,Pop Busui R,Sullivan KA.Elevated triglycerides correlate with progression of diabetic neuropathy.[J].2009,58(7).
[25]Mendoza, Saulo,Trenchevska, Olgica,King, Sarah M.,etc.Changes in Low-density Lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions[J].2017,11(1).
[26]Lamprea-Montealegre, Julio Alejandro,Staplin, Natalie,Herrington, William G.,etc.Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD[J].2020,15(1).
[27]Saeed, Anum,Feofanova, Elena V.,Yu, Bing,etc.Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease[J].2018,72(2).
[28]Fiona, Bragg,Liming, Li,Ling, Yang,etc.Risks and Population Burden of Cardiovascular Diseases Associated with Diabetes in China: A Prospective Study of 0.5 Million Adults.[J].2016.
[29]Berkelmans, Gijs F. N.,Gudbjornsdottir, Soffia,Visseren, Frank L. J.,etc.Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus[J].2019,40(34).
[30]Nakajima K,Nakano T,Moon HD.The correlation between TG vs remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers.[J].2009,404(2).
[31]Kevin Jon Williams,Peter Cheung,Kongwang Hu,etc.Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1[J].2018,38(1).
[32]Hayashi Toshiyuki,Fukui Tomoyasu,Nakanishi Noriko,etc.Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin[J].2017,16(1).
[33]Hao, Shen,Yan, Xu,Jingfen, Lu,etc.Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients.[J].2016,(1).
[34]Vallejo-Vaz, Antonio J.,Barter, Philip,Hovingh, G. Kees,etc.Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial[J].2018,138(8).
[35]Chait, Alan,Ginsberg, Henry N.,Vaisar, Tomas,etc.Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease[J].2020,69(4).
[36]Naveed,Sattar,Araz,Rawshani,Stefan,Franzén,etc.Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks.[J].2019,139(19).
[37]Terry T,Raravikar K,Chokrungvaranon N,etc.Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.[J].2012,14(1).
[38]Zoungas, Sophia,Arima, Hisatomi,Gerstein, Hertzel C.,etc.Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials[J].2017,5(6).
[39]Quispe, Renato,Al-Hijji, Mohammed,Swiger, Kristopher J.,etc.Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9[J].2015,9(4).
[40]Landray,M.J.,Haynes,R.,Hopewell,J.C.,etc.Effects of extended-release niacin with laropiprant in high-risk patients[J].2014,371(3).
[41]Brian C, Callaghan,Rong, Xia,Mousumi, Banerjee,etc.Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status.[J].2016.
[42]Sharma Tarun,Swaminathan Gayathri,Srinivasan Sangeetha,etc.Influence of serum lipids on the incidence and progression of diabetic retinopathy and macular oedema: Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular genetics Study-II[J].2017,45(9).